Cytosorbents Corp
CTSO · XNASCIK 1175151fmd_10HR55GAQCRZFXTJXG60P6KSSAManufacturing · Surgical & Medical Instruments & ApparatusTemplate: Standard
Coverage: Jan 01, 1998 to Jun 30, 2026, 77 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 10 | 15 | 23 | 25 | 41 | 43 | 35 | 31 | 36 | 37 |
| Cost of revenue | 4 | 6 | 7 | 7 | 11 | 11 | 14 | 9 | 11 | 11 |
| Gross profit | 6 | 10 | 15 | 18 | 30 | 32 | 21 | 22 | 25 | 26 |
| Research and development | 4 | 3 | 8 | 12 | 9 | 16 | 15 | 16 | – | – |
| Selling, general and administrative | 12 | 15 | 21 | 22 | 28 | 36 | 34 | 38 | 34 | 36 |
| Total operating expenses | 17 | 19 | 31 | 37 | 40 | 55 | 52 | 54 | 41 | 41 |
| Operating income | (11) | (10) | (16) | (19) | (10) | (23) | (32) | (32) | (16) | (15) |
| Interest expense | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | 1 | (2) | (1) | 1 | (3) | (2) | 2 | (6) | 6 |
| Income before taxes | (12) | (9) | (18) | (20) | (9) | (25) | (34) | (30) | (22) | (9) |
| Income tax expense | (0) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) | (0) |
| Net income from continuing operations | (12) | (8) | (17) | (19) | (8) | (25) | (33) | (29) | (21) | (8) |
| Net income | (12) | (8) | (17) | (19) | (8) | (25) | (33) | (29) | (21) | (8) |
| Net income to common shareholders | (12) | (9) | (17) | (19) | (8) | (25) | (33) | (29) | (21) | (8) |